Country: United Kingdom
Language: English
Source: MHRA (Medicines & Healthcare Products Regulatory Agency)
Clindamycin hydrochloride
Somex Pharma
J01FF01
Clindamycin hydrochloride
150mg
Capsule
Oral
No Controlled Drug Status
Valid as a prescribable product
BNF: 05010600; GTIN: 15060089611179 15060089611186
Package leaflet: Information for the patient Clindamycin 75 mg Capsules, hard Clindamycin 150 mg Capsules, hard Clindamycin 300 mg Capsules, hard Clindamycin Read all of this leaflet carefully before you start taking this medicine because it contains important information for you. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. What is in this leaflet 1. What Clindamycin is and what it is used for 2. What you need to know before you take Clindamycin 3. How to take Clindamycin Capsules 4. Possible side effects 5. How to store Clindamycin Capsules 6. Contents of the pack and other information 1. What Clindamycin is and what it is used for Clindamycin Capsules contain clindamycin which is an antibiotic used in the treatment of serious bacterial infections. 2. What you need to know before you take Clindamycin Do not take Clindamycin Capsules: • if you are allergic to clindamycin, lincomycin or any of the other ingredients of this medicine listed in section 6. Warnings and precautions Talk to your doctor or pharmacist before taking Clindamycin Capsules if: • you have diarrhoea or usually get diarrhoea when you take antibiotics or have ever suffered from problems with your stomach or intestines. If you develop severe or prolonged or bloody diarrhoea during or after using Clindamycin Capsules tell your doctor immediately since it may be necessary to interrupt the treatment. This may be a sign of bowel inflammation (pseudomembranous colitis) which can occur following treatment with antibiotics. • you suffer from problems with your kidneys or liver. • you suffer from asthma, eczema or hayfever. • you develop any severe skin reactions or hypersens Read the complete document
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Clindamycin 150mg Capsules, hard 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Clindamycin 150mg Capsules, hard Each capsule contains clindamycin hydrochloride equivalent to 150 mg clindamycin. Excipient with known effect Each capsule contains 114.65 mg lactose monohydrate equivalent to 108.92 mg of lactose (see section 4.4). For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Capsule, hard. Clindamycin 150mg Capsules, hard Size ‘1’ hard gelatin white capsules with marking ‘I 62’ on cap. 4 CLINICAL PARTICULARS 4.1 Therapeutic indications Antibacterial. Serious infections caused by susceptible Gram-positive organisms, staphylococci (both penicillinase- and non-penicillinase-producing), streptococci (except Streptococcus faecalis) and pneumococci. It is also indicated in serious infections caused by susceptible anaerobic pathogens. Clindamycin does not penetrate the blood/brain barrier in therapeutically effective quantities. 4.2 Posology and method of administration Posology Adults: Moderately severe infection, 150 - 300 mg every six hours; severe infection, 300 - 450 mg every six hours. Elderly patients: The half-life, volume of distribution and clearance, and extent of absorption after administration of clindamycin hydrochloride are not altered by increased age. Analysis of data from clinical studies has not revealed any age-related increase in toxicity. Dosage requirements in elderly patients, therefore, should not be influenced by age alone. Paediatric population: 3 - 6 mg/kg every six hours depending on the severity of the infection. Dosage in Renal/Hepatic Impairment: Clindamycin dosage modification is not necessary in patients with renal or hepatic insufficiency. Note: In cases of beta-haemolytic streptococcal infection, treatment with Clindamycin Capsules should continue for at least 10 days to diminish the likelihood of subsequent rheumatic fever or glomerulonephritis. Method of administration Oral. Clindamycin Ca Read the complete document